Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types

References

• Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous cell carcinoma - similarities and differences among anatomical sites. Am J Cancer Res 2010; 1:275-300.
   Web of Science ®Google Scholar
• Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30:774-8; PMID:8176018
   PubMed Web of Science ®Google Scholar
• Czarnecki D, Staples M, Mar A, Giles G, Meehan C. Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatol Basel Switz 1994; 189:52-4.
   PubMed Web of Science ®Google Scholar
• Agada FO, Patmore H, Alhamarneh O, Stafford ND, Greenman J. Genetic profile of head and neck squamous cell carcinoma: clinical implications. J Laryngol Otol 2009; 123:266-72; PMID:18694533
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14:535-46; PMID:25056707
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-25; PMID:22960745; http://dx.doi.org/10.1038/nature11404
   PubMed Web of Science ®Google Scholar
• Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157-60; PMID:21798893; http://dx.doi.org/10.1126/science.1208130
   PubMed Web of Science ®Google Scholar
• Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie T-X, Zhang J, Wang J, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154-7; PMID:21798897; http://dx.doi.org/10.1126/science.1206923
   PubMed Web of Science ®Google Scholar
• Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell 2014; 158:929-44; PMID:25109877; http://dx.doi.org/10.1016/j.cell.2014.06.049
   PubMed Web of Science ®Google Scholar
• Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014; 509:91-5; PMID:24670651; http://dx.doi.org/10.1038/nature13176
   PubMed Web of Science ®Google Scholar
• Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, Agrawal N. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck 2013; 35:454-63; PMID:22907887
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Devarakonda S, Govindan R. Genomic landscape of squamous cell carcinoma of the lung. Am Soc Clin Oncol Educ Book ASCO Am Soc Clin Oncol Meet 2013:348-53.
   PubMedGoogle Scholar
• Rooney M, Devarakonda S, Govindan R. Genomics of squamous cell lung cancer. The Oncologist 2013; 18:707-16; PMID:23728941; http://dx.doi.org/10.1634/theoncologist.2013-0063
   PubMed Web of Science ®Google Scholar
• Schwaederle M, Vladimir L, Validire P, Hansson J, Lacroix L, Soria J-C, Pawitan Y, Kurzrock R. VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Anti-Angiogenesis Therapy. Cancer Res 2015; 75:1187–90; PMID:25672981
   PubMed Web of Science ®Google Scholar
• Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, Naing A, Falchook GS, Fu S, Piha-Paul S, et al. P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget 2013; 4:705-14; PMID:23670029
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis J. Head and neck cancer: response to p53-based therapeutics. Head Neck 2011; 33:131-4; PMID:20222046
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11:558-72; PMID:21734724
   PubMed Web of Science ®Google Scholar
• Caldon CE, Musgrove EA. Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 2010; 5:2; PMID:20180967
   PubMed Web of Science ®Google Scholar
• Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget 2015; 6:3033–42
   Web of Science ®Google Scholar
• palblociclib press release [Internet]. Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_paloma_1_evaluating_palbociclib_plus_letrozole_in_women_with_advanced_breast_cancer.
   Google Scholar
• Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle Georget Tex 2003; 2:339-45.
   PubMed Web of Science ®Google Scholar
• Averous J, Fonseca BD, Proud CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 2007; 27:1106-13; PMID:17724476; http://dx.doi.org/10.1038/sj.onc.1210715
   PubMed Web of Science ®Google Scholar
• Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011; 3:192-222; PMID:21422497
   PubMedGoogle Scholar
• Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets 2005; 9:769-90; PMID:16083342
   PubMed Web of Science ®Google Scholar
• Holsinger FC, Piha-Paul SA, Janku F, Hong DS, Atkins JT, Tsimberidou AM, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol Off J Am Soc Clin Oncol 2013; 31:e137-40.
   PubMed Web of Science ®Google Scholar
• Weina K, Utikal J. SOX2 and cancer: current research and its implications in the clinic. Clin Transl Med 2014; 3:19; PMID:25114775
   PubMedGoogle Scholar
• Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, Mikut R, Menon R, Nikolov P, Petersen K, Beschorner C, et al. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol 2011; 42:1078-88; PMID:21334718
   PubMed Web of Science ®Google Scholar
• Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 2014; 511:246-50; PMID:24909994; http://dx.doi.org/10.1038/nature13305
   PubMed Web of Science ®Google Scholar
• Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009; 41:1238-42; PMID:19801978
   PubMed Web of Science ®Google Scholar
• Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui C, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33:416-21; PMID:12590261
   PubMed Web of Science ®Google Scholar
• Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27:5115-23; PMID:18758480; http://dx.doi.org/10.1038/onc.2008.225
   PubMed Web of Science ®Google Scholar
• Nguyen B-C, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, Koster MI, Zhang Z, Wang J, Tommasi di Vignano A, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev 2006; 20:1028-42; PMID:16618808; http://dx.doi.org/10.1101/gad.1406006
   PubMed Web of Science ®Google Scholar
• Fujii Y, Yada M, Nishiyama M, Kamura T, Takahashi H, Tsunematsu R, Susaki E, Nakagawa T, Matsumoto A, Nakayama KI. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci 2006; 97:729-36; PMID:16863506; http://dx.doi.org/10.1111/j.1349-7006.2006.00239.x
   PubMed Web of Science ®Google Scholar
• Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M, Cronin MT, Lipson D, et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 2013; 5:49; PMID:23718828; http://dx.doi.org/10.1186/gm453
   PubMed Web of Science ®Google Scholar
• Suh Y, Amelio I, Guerrero Urbano T, Tavassoli M. Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis 2014; 5:e1018; PMID:24457962; http://dx.doi.org/10.1038/cddis.2013.548
   PubMed Web of Science ®Google Scholar
• Tabatabaeifar S, Kruse TA, Thomassen M, Larsen MJ, Sørensen JA. Use of next generation sequencing in head and neck squamous cell carcinomas: A review. Oral Oncol 2014; 50:1035–40; PMID:25223596
   PubMed Web of Science ®Google Scholar
• Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet 2014; 46:939-43; PMID:25086664; http://dx.doi.org/10.1038/ng.3051
   PubMed Web of Science ®Google Scholar
• Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell 2014; 158:929–44.
   Google Scholar
• Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014; 6:377-87; PMID:24440717; http://dx.doi.org/10.1016/j.celrep.2013.12.035
   PubMed Web of Science ®Google Scholar
• Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PloS One 2012; 7:e38033; PMID:22675430; http://dx.doi.org/10.1371/journal.pone.0038033
   PubMed Web of Science ®Google Scholar
• Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol Off J Am Soc Clin Oncol 2012; 30:777-82; http://dx.doi.org/10.1200/JCO.2011.36.1196
   PubMed Web of Science ®Google Scholar